Nordea Investment Management AB Purchases 174,828 Shares of Hologic, Inc. $HOLX

Key Points

• Nordea Investment Management AB increased its stake in Hologic, Inc. by 7.2%, acquiring an additional 174,828 shares, bringing their total ownership to approximately 2.59 million shares valued at $168.67 million.
• Hologic reported $1.08 EPS for the latest quarter, exceeding the consensus estimate of $1.05, with a net margin of 13.79% and revenue of $1.02 billion.
• Several analysts have raised their target prices on Hologic stock, with Argus increasing it from $80 to $90, while Citigroup upgraded their rating from "neutral" to "buy."

Nordea Investment Management AB increased its position in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 7.2% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,587,414 shares of the medical equipment provider's stock after acquiring an additional 174,828 shares during the quarter. Nordea Investment Management AB owned about 1.16% of Hologic worth $168,674,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. Chung Wu Investment Group LLC bought a new position in shares of Hologic in the second quarter valued at approximately $26,000. Zions Bancorporation National Association UT bought a new stake in Hologic during the first quarter valued at approximately $34,000. Cromwell Holdings LLC lifted its position in Hologic by 307.0% during the second quarter. Cromwell Holdings LLC now owns 578 shares of the medical equipment provider's stock valued at $38,000 after purchasing an additional 436 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich bought a new stake in Hologic during the first quarter valued at approximately $42,000. Finally, Allworth Financial LP lifted its position in Hologic by 46.0% during the first quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider's stock valued at $40,000 after purchasing an additional 216 shares during the last quarter. 94.73% of the stock is currently owned by institutional investors.

Hologic Trading Up 2.0%

Shares of HOLX opened at $69.85 on Friday. The firm has a market cap of $15.54 billion, a price-to-earnings ratio of 28.98, a PEG ratio of 2.35 and a beta of 0.63. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.81 and a current ratio of 3.55. Hologic, Inc. has a fifty-two week low of $51.90 and a fifty-two week high of $84.39. The firm has a 50 day moving average price of $67.11 and a 200-day moving average price of $63.51.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 EPS for the quarter, topping the consensus estimate of $1.05 by $0.03. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The company had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.01 billion. During the same period in the previous year, the firm earned $1.06 earnings per share. The firm's revenue for the quarter was up 1.2% on a year-over-year basis. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. As a group, equities research analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current year.

Insider Activity at Hologic

In related news, CEO Stephen P. Macmillan sold 138,358 shares of Hologic stock in a transaction on Monday, September 22nd. The shares were sold at an average price of $66.97, for a total value of $9,265,835.26. Following the transaction, the chief executive officer directly owned 1,234,624 shares of the company's stock, valued at $82,682,769.28. The trade was a 10.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 1.88% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several equities research analysts have issued reports on HOLX shares. Argus lifted their target price on shares of Hologic from $80.00 to $90.00 and gave the company a "buy" rating in a research report on Friday, September 19th. Mizuho set a $75.00 target price on shares of Hologic in a research report on Thursday, July 31st. Royal Bank Of Canada raised shares of Hologic from a "sector perform" rating to an "outperform" rating and lifted their price target for the stock from $72.00 to $87.00 in a research note on Wednesday, August 6th. Citigroup upgraded shares of Hologic from a "neutral" rating to a "buy" rating and boosted their price objective for the stock from $60.00 to $80.00 in a report on Wednesday, July 9th. Finally, Wall Street Zen lowered shares of Hologic from a "buy" rating to a "hold" rating in a report on Wednesday, October 1st. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $80.15.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.